These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10597618)

  • 1. Incidence and severity in relation to magnitude of intake above the ADI or TDI: use of critical effect data.
    Renwick AG
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S79-86. PubMed ID: 10597618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background to the ADI/TDI/PTWI.
    Herrman JL; Younes M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of intake above the ADI/TDI in relation to toxicodynamics and toxicokinetics.
    Renwick AG
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S69-78. PubMed ID: 10597617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
    Renwick AG; Walker R
    Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of excursions above the ADI: duration in relation to pivotal studies.
    Walker R
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S114-8. PubMed ID: 10597624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of excursions above the ADI. Case study: monosodium glutamate.
    Walker R
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S119-21. PubMed ID: 10597625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Needs and methods for priority setting for estimating the intake of food additives.
    Renwick AG
    Food Addit Contam; 1996; 13(4):467-75. PubMed ID: 8792138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of extreme levels of chronic food intakes.
    Chambolle M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S13-8. PubMed ID: 10597608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excursions of intake above ADI: case study on cadmium.
    Nordberg G
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S57-62. PubMed ID: 10597615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the acceptable daily intake as presently used an axiom or a dogma?
    Galli CL; Marinovich M; Lotti M
    Toxicol Lett; 2008 Aug; 180(2):93-9. PubMed ID: 18588960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080).
    Foronda NM; Fowles J; Smith N; Taylor M; Temple W; Darlington C
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):29-36. PubMed ID: 17030370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data-derived safety factors for the evaluation of food additives and environmental contaminants.
    Renwick AG
    Food Addit Contam; 1993; 10(3):275-305. PubMed ID: 8359312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of workshop on the significance of excursions of intake above the ADI.
    Larsen JC; Richold M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S2-12. PubMed ID: 10597607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.